It was a PLEASURE to host a dedicated space to explore how ctDNA can be used to evaluate treatment response during systemic therapy
We kicked off with an inspiring lecture on Common Sense Oncology, by Eva Segelov reminding us of that patient-centered outcomes must be prioritized. European Liquid Biopsy Society (ELBS) Chair Klaus Pantel shared the work in the society for the research activity. Thanks to you both for setting the scene so well for the meeting :
Patient involvement is key for successful relevant development!
Networking is key and teaming up is essential!
We dived into current evidence and ongoing research, leading to key takeaways:
Despite heterogeneity between studies, a signal is clear. Multiple systematic reviews presented by member of our Danish Clinical Network for ctDNA-RECIST Research (and nicely summerised by Malene Støchkel Frank) show that ctDNA holds great promise across the tumor types.
We need to better understand ctDNA shedding and elimination in different clinical sitiations (inspired by lecture on ctDNA biology by Catherine Alix-Panabières.)
Methodological validation and standardization remain critical (of course)
Defining ctDNA response and progression criteria is essential for both dPCR and NGS based methods. ( 
ctDNA-RECIST 
)
Exciting ongoing trials—MONDRAN (presented by Jean-Yves Pierga), DIAMOND (Aziz Zaanan), ctDNA-RECIST(Torben Hansen), and PRELUCA (Malene Støchkel Frank) — are paving the way for innovative response monitoring strategies. THANKS to the investigators for sharing their trial designs and experiences.
Pragmatic trial designs; Benjamin Victor Ineichen nicely opened for new alternative options to be explored in the future.
Aspects to adress together; Imaging and LB – optimal use of both? ctDNA in immunotherapy (thanks for sharing your interesting data Rodrigo Toledo, PhD MBA), ctDNA related-QOL studies +++ 
I was super greatful for being part of insightful discussions, sharing ambitious research directions, and for the spirit of collaboration both during and between the sessions!
A heartfelt thank you to:
The organizing committee for your expertise and dedication. Remond Fijneman, Klaus Pantel, Malene Støchkel Frank, Aziz Zaanan, Dirk Arnold
Our funders for making this meeting possible. DCCC – Danish Comprehensive Cancer Center, DCCC National Research Center for ctDNA Guided Cancer Treatment European Liquid Biopsy Society (ELBS) Kræftens Bekæmpelse
Louise Vagner Laursen for so excellent support behind the scenes.
Still much work to be done, but we are taking real steps toward bringing ctDNA-RECIST closer to clinical application. I look forward to what’s next!
Stay connected to join our up-coming webinars !
hashtag#ctDNA hashtag#CancerResearch hashtag#LiquidBiopsy hashtag#ClinicalTrials hashtag#Collaboration